# Xtant Medical Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/XTNT/xtant-medical-reports-first-quarter-2026-financial-results
Ticker: XTNT
Company: Xtant Medical
Source: Xtant Medical
Published: 2026-05-13 11:00 EST
Original Source URL: https://investor.xtantmedical.com
## Summary

Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST ® Bellows product for high-performance hemostasis; hires Dilon's U.S.

## Article Body
Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST ® Bellows product for high-performance hemostasis; hires Dilon's U.S.
## Recent Company News
- 2026-05-13 11:00 EST — [Xtant Medical Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/XTNT/xtant-medical-reports-first-quarter-2026-financial-results) — Source: Xtant Medical
- 2026-05-07 12:00 EST — [Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026](https://biopharmsignal.com/news/XTNT/xtant-medical-to-announce-first-quarter-2026-financial-results-on-may-13-2026) — Source: Xtant Medical
- 2026-05-06 12:00 EST — [Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped](https://biopharmsignal.com/news/XTNT/xtant-medical-expands-triviumtm-portfolio-with-the-commercial-launch-of-triviumtm-shaped) — Source: Xtant Medical
- 2026-04-13 13:04 EST — [Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product](https://biopharmsignal.com/news/XTNT/xtant-medical-and-dilon-technologies-announce-exclusive-u-s-distribution-agreement-for-dilon-s-hemoblastr-bellows-product) — Source: Xtant Medical
- 2026-04-09 12:00 EST — [Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial](https://biopharmsignal.com/news/XTNT/xtant-medical-and-montana-governor-s-office-of-community-service-announce-support-for-threshold-of-life-memorial) — Source: Xtant Medical
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)